Applied Immune Technologies is a biotechnology startup dedicated to pioneering innovative therapeutic solutions using specialized antibodies to combat cancer, viral, and autoimmune diseases. Established in 2006 as BioMimic Pharma and headquartered in Haifa, Israel, the company focuses on creating T-Cell Receptor-Like (TCRL) antibodies designed to target intracellular-derived peptides for therapeutic and diagnostic applications.
The last recorded investment in the company was a $4.00M Venture Round in April 26, 2010, with Pontifax as the investor. With its specialized focus on developing molecules for disease treatment and diagnostics, Applied Immune Technologies is positioned at the forefront of biotechnological innovations, making it an attractive prospect for venture capital investment.
